Morepen Laboratories Ltd

NSE
MOREPENLAB •
BUY

1W Return

-%

1M Return

-%

6M Return

-%

1Y Return

-%

3Y Return

-%

Start SIP in Morepen Laboratories Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
104.17% Gain from 52W Low
5.5
TTM PE Ratio
Below industry Median
32.9
Price to Book Ratio
Below industry Median
3.3
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is less than 1
0.4
RSI
RSI is mid-range
42.8
MFI
MFI is mid-range
56.5

Morepen Laboratories Ltd Key Financials

*All values are in ₹ Cr.

Morepen Laboratories Ltd shareholding Pattern

Promoter
38.2%
Foreign Institutions
2.1%
Domestic Institutions
2.2%
Public
57.4%

Morepen Laboratories Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
5
Bearish Moving Averages
11
5Day EMA
51.20
10Day EMA
51.70
12Day EMA
51.70
20Day EMA
51.50
26Day EMA
51.10
50Day EMA
49.40
100Day EMA
45.70
200Day EMA
41.10
Delivery & Volume
Resistance & Support
49.87
Pivot
Resistance
First Resistance
50.93
Second Resistance
52.87
Third Resistance
53.93
Support
First Support
47.93
Second support
46.87
Third Support
44.93
Relative Strength Index
42.82
Money Flow Index
56.50
MACD
0.63
MACD Signal
1.05
Average True Range
2.47
Average Directional Index
18.54
Rate of Change (21)
5.04
Rate of Change (125)
24.37

Morepen Laboratories Ltd Company background

Founded in: 1984
Managing director: Sushil Suri
Morepen Laboratories Limited is an Indiabased pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, CefpenS, DomDT, Acifix, Rabipen DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and MontelastL.The company has three stateoftheart manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling antiallergy drug globally. The company has developed a hitech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API finished dosages and a Research Centre.The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterolreducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 19911992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 19921993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride. During the year 19931994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 19941995, the company increased the installed capacity of Drugs Drug Intermediates from 305 MT to 469 MT.During the year 19951996, the company successfully launched high value and high technology products namely, Cisapride Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 19961997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency. During the year 20002001, the company increased the installed capacity of Drugs Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products.During the year 20012002, the company increased the installed capacity of Drugs Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 20042005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDAs for the molecule. During the year 20052006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and CefpenS. During the year 20062007, the company improved its presence in the key market of South East Asia, Africa Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand Dr. Morepen. During the year 20072008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system consumables), Teco Medical Instruments, Germany (for coagulation system consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment. In 2010, it launched Cardia Division for Diabetic and Cardiac products. In 2015, it started personal Grooming Division with brand GUBB USA. In 2019, it launched APIs for many antidiabetic molecules. The Company launched IntebactImun in boosting immunity of adults and kids in 2023. It started manufacturing two more products viz., Blood Pressure Monitors and Pregnancy Testing Kits in 2023.
Read More

Morepen Laboratories Ltd FAQs

Morepen Laboratories Ltd shares are currently priced at 49 on NSE and 49.05 on BSE as of 2/27/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Morepen Laboratories Ltd [MOREPENLAB] share was 93.67. The Morepen Laboratories Ltd [MOREPENLAB] share hit a 1-year low of Rs. 24 and a 1-year high of Rs. 56.4.

The market cap of Morepen Laboratories Ltd is Rs. 2504.73 Cr. as of 2/27/2024 12:00:00 AM.

The PE ratios of Morepen Laboratories Ltd is 30.85 as of 2/27/2024 12:00:00 AM.

The PB ratios of Morepen Laboratories Ltd is 3.07 as of 2/27/2024 12:00:00 AM

You can easily buy Morepen Laboratories Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
or Resume your Application
+91 -

personImage